These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 38761584)

  • 41. Targeted Degradation of MDM2 as a New Approach to Improve the Efficacy of MDM2-p53 Inhibitors.
    Wurz RP; Cee VJ
    J Med Chem; 2019 Jan; 62(2):445-447. PubMed ID: 30575392
    [TBL] [Abstract][Full Text] [Related]  

  • 42. MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future.
    Wang W; Albadari N; Du Y; Fowler JF; Sang HT; Xian W; McKeon F; Li W; Zhou J; Zhang R
    Pharmacol Rev; 2024 May; 76(3):414-453. PubMed ID: 38697854
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Affinity-based screening of MDM2/MDMX-p53 interaction inhibitors by chemical array: identification of novel peptidic inhibitors.
    Noguchi T; Oishi S; Honda K; Kondoh Y; Saito T; Kubo T; Kaneda M; Ohno H; Osada H; Fujii N
    Bioorg Med Chem Lett; 2013 Jul; 23(13):3802-5. PubMed ID: 23726030
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Reactivation of p53 gene by MDM2 inhibitors: A novel therapy for cancer treatment.
    Gupta A; Shah K; Oza MJ; Behl T
    Biomed Pharmacother; 2019 Jan; 109():484-492. PubMed ID: 30551517
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pharmacologic activation of p53 by small-molecule MDM2 antagonists.
    Shen H; Maki CG
    Curr Pharm Des; 2011; 17(6):560-8. PubMed ID: 21391906
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Targeting the ubiquitin-mediated proteasome degradation of p53 for cancer therapy.
    Devine T; Dai MS
    Curr Pharm Des; 2013; 19(18):3248-62. PubMed ID: 23151129
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Resistance mechanisms to TP53-MDM2 inhibition identified by in vivo piggyBac transposon mutagenesis screen in an Arf
    Chapeau EA; Gembarska A; Durand EY; Mandon E; Estadieu C; Romanet V; Wiesmann M; Tiedt R; Lehar J; de Weck A; Rad R; Barys L; Jeay S; Ferretti S; Kauffmann A; Sutter E; Grevot A; Moulin P; Murakami M; Sellers WR; Hofmann F; Jensen MR
    Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3151-3156. PubMed ID: 28265066
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Stapled α-helical peptide drug development: a potent dual inhibitor of MDM2 and MDMX for p53-dependent cancer therapy.
    Chang YS; Graves B; Guerlavais V; Tovar C; Packman K; To KH; Olson KA; Kesavan K; Gangurde P; Mukherjee A; Baker T; Darlak K; Elkin C; Filipovic Z; Qureshi FZ; Cai H; Berry P; Feyfant E; Shi XE; Horstick J; Annis DA; Manning AM; Fotouhi N; Nash H; Vassilev LT; Sawyer TK
    Proc Natl Acad Sci U S A; 2013 Sep; 110(36):E3445-54. PubMed ID: 23946421
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Elevated MDM2 boosts the apoptotic activity of p53-MDM2 binding inhibitors by facilitating MDMX degradation.
    Xia M; Knezevic D; Tovar C; Huang B; Heimbrook DC; Vassilev LT
    Cell Cycle; 2008 Jun; 7(11):1604-12. PubMed ID: 18520179
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Identification of a new class of natural product MDM2 inhibitor: In vitro and in vivo anti-breast cancer activities and target validation.
    Qin JJ; Wang W; Voruganti S; Wang H; Zhang WD; Zhang R
    Oncotarget; 2015 Feb; 6(5):2623-40. PubMed ID: 25739118
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Small molecule agents targeting the p53-MDM2 pathway for cancer therapy.
    Wang W; Hu Y
    Med Res Rev; 2012 Nov; 32(6):1159-96. PubMed ID: 23059763
    [TBL] [Abstract][Full Text] [Related]  

  • 52. 1,4,5-Trisubstituted Imidazole-Based p53-MDM2/MDMX Antagonists with Aliphatic Linkers for Conjugation with Biological Carriers.
    Twarda-Clapa A; Krzanik S; Kubica K; Guzik K; Labuzek B; Neochoritis CG; Khoury K; Kowalska K; Czub M; Dubin G; Dömling A; Skalniak L; Holak TA
    J Med Chem; 2017 May; 60(10):4234-4244. PubMed ID: 28482147
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Molecular hybridization design and synthesis of novel spirooxindole-based MDM2 inhibitors endowed with BCL2 signaling attenuation; a step towards the next generation p53 activators.
    Lotfy G; Abdel Aziz YM; Said MM; El Ashry ESH; El Tamany ESH; Abu-Serie MM; Teleb M; Dömling A; Barakat A
    Bioorg Chem; 2021 Dec; 117():105427. PubMed ID: 34794098
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Small-molecule inhibitors of p53-MDM2 interaction: the 2006-2010 update.
    Millard M; Pathania D; Grande F; Xu S; Neamati N
    Curr Pharm Des; 2011; 17(6):536-59. PubMed ID: 21391905
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Resistance acquisition to MDM2 inhibitors.
    Cinatl J; Speidel D; Hardcastle I; Michaelis M
    Biochem Soc Trans; 2014 Aug; 42(4):752-7. PubMed ID: 25109953
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Hitting on the move: Targeting intrinsically disordered protein states of the MDM2-p53 interaction.
    Neochoritis CG; Atmaj J; Twarda-Clapa A; Surmiak E; Skalniak L; Köhler LM; Muszak D; Kurpiewska K; Kalinowska-Tłuścik J; Beck B; Holak TA; Dömling A
    Eur J Med Chem; 2019 Nov; 182():111588. PubMed ID: 31421630
    [TBL] [Abstract][Full Text] [Related]  

  • 57. PROTAC Degraders with Ligands Recruiting MDM2 E3 Ubiquitin Ligase: An Updated Perspective.
    Han X; Wei W; Sun Y
    Acta Mater Med; 2022; 1(2):244-259. PubMed ID: 35734447
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Leveraging the multivalent p53 peptide-MdmX interaction to guide the improvement of small molecule inhibitors.
    Cheng X; Chen R; Zhou T; Zhang B; Li Z; Gao M; Huang Y; Liu H; Su Z
    Nat Commun; 2022 Feb; 13(1):1087. PubMed ID: 35228542
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Discovery of 1-arylpyrrolidone derivatives as potent p53-MDM2 inhibitors based on molecule fusing strategy.
    Li J; Wu Y; Guo Z; Zhuang C; Yao J; Dong G; Yu Z; Min X; Wang S; Liu Y; Wu S; Zhu S; Sheng C; Miao Z; Zhang W
    Bioorg Med Chem Lett; 2014 Jun; 24(12):2648-50. PubMed ID: 24813735
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Small-molecule inhibitors of the MDM2-p53 protein-protein interaction to reactivate p53 function: a novel approach for cancer therapy.
    Shangary S; Wang S
    Annu Rev Pharmacol Toxicol; 2009; 49():223-41. PubMed ID: 18834305
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.